CSIMarket
 
Medicure Inc   (MPH)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 10
 Employees 50
 Revenues (TTM) (Millions $) 17
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Medicure Inc
Medicure Inc is a pharmaceutical company that specializes in the development, production, and commercialization of innovative prescription drugs. The company focuses on cardiology and neurology therapeutic areas, aiming to provide effective treatment solutions for various cardiovascular and neurological conditions. Medicure Inc is committed to conducting rigorous research and clinical trials to ensure the safety and efficacy of their medications. Additionally, the company actively seeks out strategic partnerships and collaborations to expand its product pipeline and deliver long-term value to patients and shareholders. Overall, Medicure Inc strives to improve global healthcare by delivering high-quality, innovative pharmaceutical solutions.


   Company Address: 2 - 1250 Waverley Street Winnipeg 0 MB
   Company Phone Number: 487-7412   Stock Exchange / Ticker: MPH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -0.38%    
AZN        5.37% 
JNJ        0.56% 
NVS        1.31% 
PFE   -3.23%    
SNY   -0.41%    
• View Complete Report
   



Arrowhead Pharmaceuticals Inc

revenue fall back substantially at ARWR all along the financial time-frame ending December 31 2024

Weak orders caused improvement in losses for the fiscal period ending December 31 2024, ARWRs' net loss per share inched up to $-1.39 from $-1.24 where Revenue went down by -29.597 % to $2.50 million from $3.55 million a year before. In contrast to the the Arrowhead Pharmaceuticals Inc s' development the rest ofMajor Pharmaceutical Preparations sector, recorded a revenue 2.68% improvement compared to the similar period a year before in the first quarter of 2025.

Iterum Therapeutics Plc

The Major Pharmaceutical Preparations company added positive story for the investors, presenting a relevant improvement in financial interval ending December 31 2024 with operating shortfall of $-3.67 million

The shareholders haven't anticipated some changes at the top-line during the the October to December 31 2024 reporting cycle at the ITRM. However, they monitor the company's operating shortfall which was at $-3.67 million, during the matching time.

Scpharmaceuticals Inc

Scpharmaceuticals Inc has failed to turn into profitability despite the epic Surge in revenue in the most recent fiscal period

Scpharmaceuticals Inc announced very strong Revenue elevation of 164.12 % year on year to $10.03 million in the third quarter of 2024, but increased a deficit per share at $-0.75. Major Pharmaceutical Preparations company's business advanced at higher rate in contrast to the the revenue at almost all of the Major Pharmaceutical Preparations sector peers, in the third quarter of 2024 the two third entities in Major Pharmaceutical Preparations sectors saw the business elevation of 9.75% relative to the similar period a year ago.

Eledon Pharmaceuticals Inc

Major Pharmaceutical Preparations company, contraction in the operating results during the financial third quarter of 2024

The Major Pharmaceutical Preparations industry experts start to analyze the third quarter of 2024 performance. Today those experts observe operating shortfall of $-20.51 million, from the company, which has not specified any revenue so far, for the respective July to September 30 2024 quarter.

Terns Pharmaceuticals Inc

In thethird quarter of 2024 earnings season operating deficit showed enhancement to $-33.184 million, at the Terns Pharmaceuticals Inc

After the leaders in the Major Pharmaceutical Preparations industry, a few overlooked corporations are publishing their numbers. TERN mentioned it has clinched operating deficit of $-24.939 million, for the third quarter of 2024.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com